Physician profile
Rita A Sharma
NPI 1205817038
$8,680.61
in general payments reported to CMS, 2019-2025
47 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $876 · 2021: $1,556 · 2022: $1,400 · 2023: $1,297 · 2024: $1,386 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,237.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,046.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,034.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $914.18 | 2020-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $625.42 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Amgen INC. | $425.64 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Madrigal Pharmaceuticals | $385.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $307.01 | 2021-2025 | Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $296.96 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $277.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.08 | 2022-2025 | |
| Pfizer INC. | $222.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $221.65 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Dexcom, INC. | $144.61 | 2021-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $131.07 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.15 | 2020-2025 | Xifaxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.